Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 3/20 | 0.66 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.37 |
| ▸ | DCK | P27707 | 2/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599699 | 1.00 | POLG (0.66) | POLGALBP2RY2P2RY4P2RY6 | |
| SCHEMBL599687 | 0.89 | POLG (0.51) | POLGALBDCK | |
| SCHEMBL599686 | 0.89 | POLG (0.51) | POLGALBDCK | |
| SCHEMBL14354922 | 0.85 | POLG (0.62) | POLGALBP2RY2P2RY4P2RY6 | |
| SCHEMBL13924226 | 0.84 | POLG (0.61) | POLGALBP2RY2P2RY4P2RY6 | |
| SCHEMBL25492503 | 0.82 | POLG (0.70) | POLGP2RY2P2RY4P2RY6 | |
| SCHEMBL8409011 | 0.82 | POLG (0.70) | POLGP2RY2P2RY4P2RY6 | |
| SCHEMBL8409014 | 0.82 | POLG (0.70) | POLGP2RY2P2RY4P2RY6 | |
| SCHEMBL6714480 | 0.81 | POLG (0.64) | POLGP2RY2P2RY4P2RY6P2RX1 | |
| SCHEMBL13199313 | 0.81 | POLG (0.71) | POLGALBP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114994-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-11 | — | — | US | disclosed |
| US-7495006-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2009-02-24 | — | — | US | disclosed |
| US-20060223835-A1 | 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | HAVCR2, PNP, PCNA | POLG 930/4885ALB 2985/4885P2RY2 2433/4885 |
| US-20060223835-A1 | 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | HAVCR2, PNP, DCTD | POLG 922/4885ALB 2897/4885P2RY2 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.